הכנסה תפעולית לפני ניכוי פחת: viraxbiolabs.com (VRAX)

Virax Biolabs Group (VRAX) delegates the manufacturing of test systems to external contractors, focusing instead on marketing and R&D. EBITDA cash flow reflects operating revenue volatility, while the 0.00 value aligns with the current metric. The neutral geopolitical status of biomedicine ensures business stability. Management plans to scale the diagnostic network and expand into emerging regions to combat infections.

Virax Biolabs Group is establishing a sustainable cash flow driven by patent protection for its test systems and long-term government contracts in the biosafety sector. This indicator captures the actual volume of operating funds, stripped of accounting accruals, allowing investors to identify points of fundamental business undervaluation via current EBITDA based on the company's ability to generate physical liquidity.